Paediatric cancer hospital St. Jude Children's Research Hospital reported on Monday that it intends to develop a USD412m 625,000-square-foot advanced cancer research centre at its campus.
Slated to break ground in spring 2018 and open in 2021, the advanced research centre is a major component of the company's USD1bn capital expansion plans. The new centre will house cutting-edge technologies and resources that can transform science and accelerate the pace of discovery. The exploration and discovery centre will cultivate transformative research and collaboration and attract scientists and clinicians.
The company's new advanced research centre will treat childhood cancer and other life-threatening diseases. The interactive and interdisciplinary environment is designed specifically for generating new ideas and teamwork. Its labs and spaces will enable researchers to collaborate openly and across departments.
In addition, the company's new advanced research centre will feature state-of-the-art labs focusing on immunology, neurobiology, cell and molecular biology, gene editing, metabolomics, advanced microscopy, epigenetics, genomics, immunotherapy as well as RNA biology.
Developed by The Crump Firm, lead architect on the project and Jacobs Engineering, experts in lab design, the advanced research center propels St. Jude for the long term, accommodating growth for the next 20 years and beyond, with two of eight floors slated for future expansion and evolving technology.
Jacabio reports pre-clinical data for JAB-23E73 pan-KRAS inhibitor at international conference
Orion secures exclusive commercial licence for Abzena cancer antibody
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
BD launches IVDR-certified self-collection solution to expand global access to HPV testing
Ipsen to acquire French biotech ImCheck Therapeutics in deal worth up to EUR1billion
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
Alligator Bioscience granted US patent for ATOR-4066 bispecific antibody
Citius Oncology and McKesson sign US distribution agreement for LYMPHIR
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck reports long-term survival benefits of Keytruda in non-small cell lung cancer
Avacta reports promising Phase 1a data for faridoxorubicin at ESMO 2025